All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Management of drug-related adverse events in patients with steroid-refractory cGvHD
By Ella Dixon
Bookmark this article
During the GvHD Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the management of drug-related adverse events in patients with steroid-refractory chronic graft-versus-host disease (cGvHD). The recorded discussion was chaired by Zinaida Peric, and featured Yi-Bin Chen, Amin Alousi, Florent Malard, Mohamad Mohty, Arnon Nagler, Steven Pavletic, and Robert Zeiser.
Management of drug related adverse events in patients with steroid refractory GvHD
The steering committee discussed how to define steroid intolerance and how this definition can change for each patient based on side effects and treatment scheduling. In addition, the steering committee spoke about how to approach steroid tapering and appropriate dosing of steroids, and how to evaluate the response of steroids and to ruxolitinib. They also discussed the choice of drug for cGvHD, taking patient factors and side effects into account.
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox